AnalystsInsight

Mate Nemes (UBS): Analyst Track Record and Price‑Target Accuracy

Mate Nemes is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Mate covers, how Mate’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Published Updated 2 min readHow we research

Key takeaways

  • Mate Nemes ranks among the top 50 financials analysts in Exent’s ranking, scored on a 7‑year backtest.
  • The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
  • Most‑covered stocks: ETR-DBK, SWX-PGHN, ETR-CBK, SWX-BAER.
  • In the past year Mate’s ratings were 83% Buy, 17% Hold and 0% Sell.

Mate Nemes’s track record at a glance

Mate Nemes of UBS ranks among the top 50 financials analysts in Exent’s ranking, with a focus on financials. The top of the ranking is what Exent Gems follows, so Mate’s exact rank, hit rate and live calls are for members.

MetricMate NemesAll analysts
Exent rank—
Price‑target hit rate53.6%
Calls up after 12 months64.6%
Median 12‑month return of calls+13.4%
Median days to hit target91 days
Stocks covered18—

How fast price targets were reached

Time to reach the targetMate Nemes
Under 30 days—
30–90 days—
90–180 days—
Over 180 days—

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Mate Nemes covers most

ETR-DBK · SWX-PGHN · ETR-CBK · SWX-BAER · ETR-0B2 · OTC-EBKOF · EPA-GLE · SWX-EFGN

In the past year Mate’s ratings were 83% Buy, 17% Hold and 0% Sell.

Mate Nemes’s latest ratings

DateStockActionRatingPrice target
Aug 25, 2026SWX-EFGNReiterated: HoldHold$17.20
Jul 30, 2026ETR-DBKReiterated: BuyBuy$37.00
Jul 8, 2026SWX-PGHNDowngraded: HoldHold$705.00
May 13, 2026LON-0NXRMaintained: BuyBuy$52.00
May 13, 2026LON-0NXRMaintainedBuy$52.00
Apr 29, 2026ETR-DBKReiterated: BuyBuy$34.00
Apr 29, 2026ETR-DBKMaintained: BuyBuy$34.00
Apr 29, 2026ETR-DBKMaintainedBuy$34.00
Apr 24, 2026ETR-DBKMaintained: BuyBuy$34.00
Apr 24, 2026ETR-DBKReiterated: BuyBuy$34.00
Apr 24, 2026ETR-DBKMaintainedBuy$34.00
Apr 20, 2026ETR-0B2Maintained: BuyBuy$156.00
  • Aug 25, 2026
    Stock
    SWX-EFGN
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $17.20
  • Jul 30, 2026
    Stock
    ETR-DBK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $37.00
  • Jul 8, 2026
    Stock
    SWX-PGHN
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $705.00
  • May 13, 2026
    Stock
    LON-0NXR
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $52.00
  • May 13, 2026
    Stock
    LON-0NXR
    Action
    Maintained
    Rating
    Buy
    Price target
    $52.00
  • Apr 29, 2026
    Stock
    ETR-DBK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $34.00
  • Apr 29, 2026
    Stock
    ETR-DBK
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $34.00
  • Apr 29, 2026
    Stock
    ETR-DBK
    Action
    Maintained
    Rating
    Buy
    Price target
    $34.00
  • Apr 24, 2026
    Stock
    ETR-DBK
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $34.00
  • Apr 24, 2026
    Stock
    ETR-DBK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $34.00
  • Apr 24, 2026
    Stock
    ETR-DBK
    Action
    Maintained
    Rating
    Buy
    Price target
    $34.00
  • Apr 20, 2026
    Stock
    ETR-0B2
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $156.00

Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 22, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Mate Nemes’s full record and latest ratings, without the 30‑day delay.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Mate Nemes ranks among the top 50 financials analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Mate Nemes’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 53.6% of the time.

Mate Nemes (UBS) covers 18 stocks, mostly in financials. The most frequently rated are ETR-DBK, SWX-PGHN, ETR-CBK, SWX-BAER, ETR-0B2.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.